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Background: High sensitive CRP (hs-CRP) is used as a marker of systemic 
inflammation in chronic obstructive pulmonary disease (COPD).  However, we 
hypothesize that the raised hs-CRP is not closely related to the multiple 
consequences of COPD.  
This study was undertaken to investigate the association of COPD assessment 
test (CAT) score with SpO2, FEV1, body mass index (BMI), obstruction, dyspnea 
and exercise capacity (BODE) index and COPD exacerbation rate and compare 
it with the association to serum hs-CRP level.    
Materials and Methods: Sixty patients with stable COPD referred to the 
pulmonology clinic of Ardabil Imam Khomeini Hospital were included in this 
study. SpO2, 6-minute walk distance (6MWD), body mass index, BODE index, 
and pulmonary function test as well as exacerbation rate were determined in 
COPD patients. Then, the CAT questionnaire was completed by patients. Serum 
level of hs-CRP was measured in all patients and 15 controls. We statistically 
compared the relationships and correlations among the variables. 
Results: Hs-CRP level was significantly raised in patients (P=0.005). In these 
patients, the correlation of hs-CRP level with BODE index was significant 
(P=0.008). However, the correlation of hs-CRP with SpO2 and FEV1 was not 
significant (P=0.47 and P=0.17, respectively). Also, the correlation of CAT score 
with SpO2, FEV1, BODE index, and exacerbation rate in the previous year was 
significant (P<0.001, P<0.001, P<0.001 and P=0.017, respectively). 
Conclusion: SpO2, FEV1, BODE index and exacerbation rate are more correlated 
with CAT scores than with the serum level of hs-CRP in stable COPD patients. 
The findings of this study should be considered in management of stable COPD 
patients. 
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INTRODUCTION 
COPD is the fourth cause of mortality afflicting over 
200 million people around the world (1,2). It is 
characterized by irreversible airflow limitation and is 
associated with a systemic inflammatory response.  It is 
estimated to rank the third most common cause of death in 
the world by 2020 (3). COPD has a major negative impact 
on health and quality of life (4). There is a list of major risk 
factors for COPD in which, smoking holds the first rank 
(5). Other relatively less common risk factors for COPD 
include respiratory infections, occupational exposure, air 
pollution, and genetics (6). 
It is well known that in patients with COPD, systemic 
inflammation in addition to local airway inflammation 
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depending on the severity of COPD, contribute to  
pulmonary and extra-pulmonary complications of the 
disease such as pulmonary function impairment, exercise 
intolerance (even regardless of lung function impairment 
level), disease exacerbation, hypoxemia, muscle atrophy, 
activity confinement, cachexia, and osteoporosis (7-10).  
The most common causes of mortality in patients with 
COPD include respiratory insufficiency and cardiovascular 
complications; both of which can be ascribed to the 
systemic inflammation and its severity (11). 
Systemic inflammation can be determined with 
markers of inflammation such as CRP, interleukins (IL), 
and TNFα. Among these markers, hs-CRP is as an 
important one and is a widely accepted biomarker related 
to the airflow obstruction (7).  
However, the potential role of hs-CRP as a marker to 
reflect all aspects of pulmonary and extra-pulmonary 
complications in COPD and its prognostic value in COPD 
need further investigation.  
COPD assessment test (CAT) is a new questionnaire for 
COPD patients. It is a simple method for assessing the 
impact of COPD on health and has similar discriminative 
properties to the much more complex St. George`s 
Respiratory Questionnaire (SGRQ) to measure the impact 
of COPD on individual patient’s health (12-15). 
This study was undertaken to investigate the 
association of hs-CRP levels and CAT scores with COPD 
impairment variables such as hypoxia severity (SpO2), 
FEV1, BODE index and the frequency of exacerbations.  
  
MATERIALS AND METHODS 
This cross sectional study was conducted on 60 patients 
with COPD diagnosed on the basis of the criteria 
suggested by the American Thoracic Society (ATS) for 
diagnosis and treatment of COPD (16). All the patients 
with symptoms suggestive of COPD underwent 
spirometry before and after inhalation of bronchodilator. 
All the participants chosen for this study had stable 
COPD and had been referred to the pulmonology clinic of 
Ardabil Imam Khomeini Hospital.  All subjects with a 
history of asthma, bronchiectasis, tuberculosis and 
debilitating inflammatory diseases such as arthritis, 
connective tissue disorders, inflammatory bowel disease or 
malignancy and patients in the exacerbation phase or with 
a hospitalization record during the past two months were 
excluded from this study.   
All participants signed a consent form for participation 
in the study. Subsequently, their demographic data 
(including sex, weight, height, age and the amount and 
duration of smoking) were recorded.  
Each patient was assigned a BODE score. The BMI was 
calculated and the degree of airflow obstruction was 
determined by means of FEV1; dyspnea was determined 
using the MMRC dyspnea scale and exercise capacity was 
determined with the distance walked in 6 minutes 
(6MWT). For each value of FEV1, MMRC dyspnea scale 
and 6MWT, each patient received points that varied from 0 
to 3. For the BMI, each patient received 0 or 1 point. The 
points for each component of the BODE index were added, 
and the final score varied between 0 and 10 points for each 
patient. In addition, the BODE score was classified in 
quartiles: quartile I included patients with a score of 0–2; 
quartile II, 3–4 points; quartile III, 5–6 points; and quartile 
IV, 7–10 points (17).  
Oxygen saturation was measured in all patients by 
pulse-oximetry. Exacerbations were defined using the 
criteria developed by Global Initiative for Obstructive 
Lung Disease (GLOD) (18). 
CAT is a recently introduced, patient-completed 
instrument to assess and quantify health-related quality of 
life and symptom burden in patients with COPD (13,19). It 
comprises 8 questions, each presented as a semantic 6-
point (0–5) differential scale, providing a total score out of 
40 (20). All patients completed the CAT questionnaire. The 
total CAT score was calculated for each individual by 
summing the points for each variable.  The CAT score was 
classified into four groups of 1) low, 2) medium, 3) high, 
and 4) very high based on the impact level of disease on 
health status (13). 
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For measurement of the serum level of hs-CRP, blood 
samples were collected from the patients and a control 
group of 15 healthy non-smokers who were over 40 years 
old and did not have any record of specific illness. Hs- CRP 
test was done by means of multidetector BT-3000, using 
immunoturbidimetric method, 10 minutes after incubation 
over 5μL serum, and reading after 290 seconds. 
Variables were presented as percentage and mean± SD 
depending on their distributions. 
Differences between means were analyzed with 
Student's t-test and reported with 95% confidence interval.  
ANOVA was applied with 95% confidence interval for the 
estimation of differences. In order to evaluate the 
correlation between parametric variables, the Pearson's 
correlation coefficient was utilized. SPSS was used for 
analysis of data. P value less than 0.05 in all analyses was 
considered statistically significant.  
 
RESULTS 
A total of 60 patients were recruited out of which, 54 
(90%) were males and 6 (10%) were females. Also, 15 
healthy subjects comprised the control group. The mean ± 
SD hs-CRP level was 4.86±6.42 mg/L in patients with 
COPD and 1.96±2.16 mg/L in healthy controls. The 
difference between the two groups was statistically 
significant (P=0.005). Physiologic and clinical 
characteristics of patients are presented in Table 1.  
The patients’ CAT scores ranged from 5 to 33 with a 
mean±SD of 18.82±6.86. The number of patients in CAT 
groups of 1, 2, 3 and 4 was 2, 37, 18 and 3, respectively. The 
majority of patients (34 subjects out of 60) were in the first 
group of 6MWD test (over 350 meters).  
The hs-CRP level had a statistically significant 
correlation with BODE severity (r=0.34, P=0.008). Groups 
with higher BODE score had higher hs-CRP (Figure 1). 
Drawing a comparison between patients’ CAT scores 
and their BODE index scores revealed a significant 
relationship between CAT scores and disease severity in 
patients based on the BODE criterion (r=0.65, P<0.001) 
(Figure 2).  
 
Table 1. The physiologic and clinical characteristics of patients 
 
 Subjects (Number/percent) Mean± SD 
Age (years)  60.53±13.06 
Sex (M/F) 54/6  
Smoking history   
Current smoker 44(74%)  
Ex-smoker 14(23%)  
Non smoker 2(3%)  
BMI(Kg/m2)   
BMI≤21 4(6.7%) 
BMI>21 56(93.3%) 
25.18±3.37 
FEV1/FVC%  63.02±7.57 
FEV1% predict  56.71±18.22 
MMRC(dyspnea scale)  1.62±0.88 
6MWD(meter)  346±182 
SpO2  93.33±3.87 
CAT score   
Mild 2(3.3%) 7.00±2.82 
Moderate 37(61.7%) 15.14±3.94 
Severe 18(30%) 25.50±2.45 
Very severe 3(5%) 32.00±1.00 
BODE score   
Quartile I (0-2) 30(50%) 0.90±0.76 
Quartile II (3-4) 17(28.3%) 3.29±0.47 
Quartile III (5-6) 7(11.7%) 5.57±0.53 
Quartile IV (7-10) 6(10%) 7.50±0.55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 1. The relationship between hs-CRP and BODE groups 
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Figure 2. The relationship between BODE score and CAT groups 
 
The relationship between hs-CRP and BMI was 
examined. ANOVA did not reveal any significant 
relationship between hs-CRP and low (less than 21) / high 
(≥ 21) BMI in patients (P=0.16) (Table 3). Similarly, the 
relationship between CAT score and BMI was not 
statistically significant (r=-0.01, P=0.89).  
The mean±SD of FEV1/FVC% and FEV1% predicted 
was 63.21±7.53 and 56.71±18.22, respectively in patients 
with COPD. The correlation analysis conducted on hs-CRP 
and FEV1 did not indicate any significant relationship (r=-
0.17, P=0.17). However, the correlation coefficient indicated 
a significant relationship between FEV1 and CAT scores 
(r=-0.49, P<0.001).  
There was also a significant relationship between CAT 
scores and MMRC amounts (P<0.001). The correlation 
between hs-CRP and MMRC did not reach significance 
(P=0.06).  
The correlation between hs-CRP and 6MWD was 
statistically significant (r=-0.29, P=0.02), and also there was 
a significant relationship between CAT scores and 6MWD 
(r=-0.47, P<0.001). 
The examination of the correlation of hs-CRP level with 
SpO2 did not display any significant relationship (r=-0.09, 
P=0.47). Whereas, CAT scores and SpO2 values were 
significantly correlated (r= -0.45, P<0.001). 
The frequency of exacerbations (number of 
hospitalizations per  year) did not indicate any statistically 
significant relationship with hs-CRP levels (r=0.10 and 
P=0.42) but had a statistically significant correlation with 
CAT scores of the subjects (r= 0.30, P<0.017). Tables 2 and 3 
display hs-CRP and CAT score relationships with disease 
severity variables. The analysis also showed a weak 
correlation between serum hs-CRP level and CAT score 
(r=0.25, P=0.05). 
 
Table 2. The relationship of serum hs-CRP and CAT score with variables 
 
Variable CAT Hs-CRP 
 P-value Correlation P-value Correlation 
BODE 0.33 0.008 0.65 <0.001 
FEV1 -0.17 0.17 -0.49 <0.001 
6MWD -0.29 0.02 -0.47 <0.001 
SpO2 -0.09 0.47 -0.45 <0.001 
Exacerbation frequency 
in the past year  
0.10 0.42 0.30 0.017 
 
Table 3. The relationship of hs-CRP level and each conducted test  
 
Variables  Patients (No.) Mean hs-CRP ±SD P Value* 
Subjects 6MWD/meters 
First group ≥ 350  34 3.50±4.55 
Second group 250-349 9 5.96±8.03 
Third group 150-249 9 2.95±3.73 
Fourth group < 150 8 11.53±9.71 
0.008 
BODE score 
1th Quartile 30 3.50±4.87 
2th Quartile 17 3.87±5.88 
3th Quartile 7 7.91±7.15 
4th Quartile 6 10.88±10.53 
0.03 
*: shows between-group differences 
 
DISCUSSION 
The results of our study demonstrated a significant 
relationship between the CAT scores and exacerbation 
frequency in the past year.  CAT as an instrument, which 
evaluates severity of impact of disease on quality of life, 
can be used as a tool for evaluating multiple effects of 
disease on different aspects of life such as sleep, activity, 
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energy and dyspnea. Also, CAT can be helpful for 
assessing the effectiveness of treatment during the course 
of disease and progression and severity of disease in 
COPD patients.  
Furthermore, in this study a significant relationship 
was found between the CAT scores and FEV1. This is in 
line with the results of a study by Ghobadi et al (21). 
Another study by Jones, however, found weak correlations 
between CAT scores and FEV1 values (12).  
There was a significant difference in the hs-CRP levels 
between the two groups. It means that the level of hs-CRP 
in patients with COPD was higher than that in the control 
group. Gan and co-workers found elevated levels of hs-
CRP in COPD patients (5). 
However, our study did not show any significant 
relationship between hs-CRP level and the number of 
exacerbations. This is in line with the results of studies by 
Halvani et al. and Pinto-Plata et al. that found no 
relationship between the exacerbation rate and hs-CRP 
level (22,23). A study by Takemura et al. in Japan found a 
significant relationship between hs-CRP level and number 
of exacerbations (24). Likewise, Alavi et al, (2011) in Guilan 
reported hs-CRP as a predictor of exacerbation frequency 
(25).  
Lack of a relationship between hs-CRP level and 
frequency of exacerbations, as well as the inability of hs-
CRP for prediction of disease exacerbation according to 
CAT confirm our proposed hypothesis that serum level of 
hs-CRP, as an inflammatory marker, alone cannot reflect 
the effect of disease on various organs in patients with 
COPD. There are also other factors that play a role in 
development of symptoms. Existence of a relationship 
between exacerbation periods and CAT supported our 
hypothesis.  
Hs-CRP is an inflammatory factor, which is released by 
hepatocytes and its elevation can be a sign of severity of 
systemic inflammation. Some researchers showed a 
correlation between hs-CRP level and FEV1 (25-27). 
However in the present study there was no significant 
correlation between hs-CRP and FEV1. In our opinion, the 
serum hs-CRP does not adequately reflect all the 
pulmonary and extra-pulmonary manifestations of disease. 
For example, in this study the serum level of hs-CRP did 
not show a significant correlation with exacerbation rate.  
The patients’ BODE index was also calculated and the 
gained score was placed in the fourth quartile. The results 
showed that CAT score and hs-CRP levels in patients had a 
highly significant relationship with their BODE scores 
(P<0.001 and P=0.008, respectively).  
Furthermore, there was a significant correlation 
between CAT scores and 6MWD in COPD patients in this 
study. A significant relationship between 6MWD and hs-
CRP level was also found (P=0.02). All the prior studies 
have found significant relationships between CRP and 
6MWD (7). Lee et al. in 2008 conducted a study in Taiwan 
and assessed the effect of pravastatin on hs-CRP level. 
They indicted that after 6 months of pharmacotherapy, and 
retesting of 6MWD and hs-CRP, a significant change was 
observed in patients’ 6MWD test results, as their hs-CRP 
level decreased. They concluded that controlling systemic 
inflammation had a positive effect on patients' activity (28). 
The results of the current study manifested that as hs-CRP 
level increased the amount of muscular activity and 
walked distance in 6 minutes decreased.  
In the current study, the patients’ dyspnea was 
examined using MMRC scoring system and the patients 
were categorized into different stages (0–4). The results 
revealed no statistically significant correlation between hs-
CRP and MMRC scores (P=0.06). While, there was a 
significant correlation between the patients’ CAT and 
MMRC scores. Also, the Pinto-Plata’s study in 2006 did not 
find any significant correlation between hs-CRP and 
MMRC (23). 
The patients’ BMI varied from 19-34  and their hs-CRP 
and BMI were not correlated significantly (P=0.79). 
Contrary to our expectation that chronic inflammatory 
disease would result in cachexia and weight loss, studies 
by Bridevaux et al. and Pinto-Plata et al. showed contrary 
results and reported higher levels of hs-CRP in higher 
weights (23,29). On the other hand, in a study in Ohio, 
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Sahebjami and Sathianpitayakul discovered a correlation 
between dyspnea severity and lower weights. It can be 
argued that, as much as CRP level is correlated with the 
severity of COPD, in severe COPD (with higher levels of 
CRP), patients become cachectic and thin (1). Lack of a 
correlation between hs-CRP and BMI in the current study 
may be a result of presence of a large number of stage II 
and III patients and low number of stage IV patients. 
The majority of the patients were over 60 years old, 
which is similar/parallel to the characteristic of 
participants partaken in other studies and indicates that in 
Iran, like other countries, COPD mostly occurs in elderly 
men (2). 
The mean hs-CRP level in the current study was not 
significantly different between males and females. 
Previous studies on this issue have presented contradictory 
results. For example, Kony et al, in their study revealed 
that hs-CRP level in females was lower than that in males 
(30); while another study conducted by Bridevaux et al. 
exhibited the more frequent increase of hs-CRP level and 
decrease of FEV1 in females compared to males (29). 
Although the age of patients under study ranged from 32 
to 85, no significant relationship was detected between 
level of hs-CRP and age of patients. 
This study had some limitations. The first limitation 
was not assessing the serum level of other inflammatory 
markers such as IL-6 and TNFα to evaluate the correlation 
of these markers with CAT score, 6MWD, BODE score and 
airflow obstruction. Secondly, relatively few women were 
recruited in this study. It probably resulted in under 
diagnosis of COPD in women. 
 
CONCLUSION 
CAT can assess the severity of pulmonary and extra 
pulmonary symptoms. Moreover, it can measure an 
individual's energy and strength, energy level decease, and 
sleep disorder resulting from COPD and systemic 
inflammation.   
Hs-CRP level mainly shows the quantitative degree of 
systemic inflammation; while CAT reflects the effect of 
inflammatory markers on patients’ health status and their 
organ functions. Assessment of hs-CRP level cannot 
determine the severity of airways obstruction (FEV1) in 
patients with COPD. Considering the relationship of the 
exacerbation rate and other disease severity parameters 
determined by CAT, it may serve as a good predictor of 
patient outcome.  
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